DISC MEDICINE INC
IRONNASDAQTrading Snapshot
- Day Range
- $82.22 – $85.00
- 52-Week Range
- $40.00 – $99.50
- Volume (shares)
- 686,454
- Avg Volume (shares)
- —
- Shares Outstanding
- 44.4M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-6.57
- Dividend Yield
- —
- Dilution (1yr)
- +17.9%
DISC MEDICINE INC
IRON
StockOtter · stockotter.spaceAbout DISC MEDICINE INC
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock
WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments f
Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants
WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments f
Disc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP Transcript
Disc Medicine, Inc. (IRON) Discusses Topline Results of APOLLO Phase III Trial of Bitopertin in EPP Transcript
Disc Medicine Delivers Promise For Patients with Sunlight Sensitivity In Successful Pivotal Study
Disc Medicine Inc. (NASDAQ:IRON) on Monday reported positive topline results from its APOLLO Phase 3 trial evaluating bitopertin for erythropoietic protoporphyria, or EPP, including X-linked protoporphyria, or XLP.
Disc Medicine stock soars: take profit or buy into strength?
Disc Medicine (IRON) shares ripped higher on Monday morning after the company's experimental blood-disorder treatment, bitopertin, delivered positive Phase 3 results. In its press release, management said the APOLLO clin
Disc Medicine (IRON) Achieves Positive Phase 3 Trial Results for EPP Treatment
Disc Medicine (IRON) is experiencing a significant surge today following the announcement of positive results from its pivotal Phase 3 APOLLO trial for bitopert